195 related articles for article (PubMed ID: 37225847)
1. Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition.
Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
3. Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.
Preston SEJ; Emond A; Pettersson F; Dupéré-Richer D; Abraham MJ; Riva A; Kinal M; Rys RN; Johnson NA; Mann KK; Del Rincón SV; Licht JD; Miller WH
Mol Cancer Ther; 2022 Apr; 21(4):511-521. PubMed ID: 35086959
[TBL] [Abstract][Full Text] [Related]
4. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
7. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.
Li C; Wang Y; Gong Y; Zhang T; Huang J; Tan Z; Xue L
Clin Epigenetics; 2021 Mar; 13(1):62. PubMed ID: 33761979
[TBL] [Abstract][Full Text] [Related]
8. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
10. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
11. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.
Johnson DP; Spitz GS; Tharkar S; Quayle SN; Shearstone JR; Jones S; McDowell ME; Wellman H; Tyler JK; Cairns BR; Chandrasekharan MB; Bhaskara S
Oncotarget; 2015 Mar; 6(7):4863-87. PubMed ID: 25605023
[TBL] [Abstract][Full Text] [Related]
12. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Xie S; Wei F; Sun YM; Gao YL; Pan LL; Tan MJ; Wang SD; Ding J; Chen Y
Haematologica; 2020 Apr; 105(4):1021-1031. PubMed ID: 31289198
[TBL] [Abstract][Full Text] [Related]
14. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
15. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H; Stephenson RE; Reynolds R; Shah S; Puri R; Butler SD; Trujillo-Alonso V; Teater MR; van Besien H; Gibbs-Curtis D; Ueno H; Parvin S; Letai A; Mathew S; Singh A; Cesarman E; Melnick A; Giulino-Roth L
Blood Adv; 2020 Oct; 4(20):5226-5231. PubMed ID: 33104794
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
17. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
Li C; Song J; Guo Z; Gong Y; Zhang T; Huang J; Cheng R; Yu X; Li Y; Chen L; Ma X; Sun Y; Wang Y; Xue L
Front Immunol; 2022; 13():857808. PubMed ID: 35432300
[TBL] [Abstract][Full Text] [Related]
18. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
Tong KI; Yoon S; Isaev K; Bakhtiari M; Lackraj T; He MY; Joynt J; Silva A; Xu MC; Privé GG; He HH; Tiedemann RE; Chavez EA; Chong LC; Boyle M; Scott DW; Steidl C; Kridel R
Clin Cancer Res; 2021 Oct; 27(19):5401-5414. PubMed ID: 34168051
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
20. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
